Protein-protein interactions have emerged as an important mechanism providing for specificity in cellular signal transduction. Two splice variants of type I cGMP-dependent protein kinase (PKG I and I ) differ only in their Nterminal ~100 amino acids which mediate binding to different target proteins; PKG I , but not I , binds to the general transcriptional regulator TFII-I and the inositol 1,4,5-trisphosphate receptor-associated PKG substrate IRAG. Using a combination of site-directed mutagenesis and in vitro binding assays, we identified a group of acidic amino acids in the N-terminal leucine zipper dimerization domain of PKG I required for its binding to both TFII-I and IRAG. Small clusters of basic amino acids in possible -helical regions in TFII-I and IRAG were found to mediate their interaction with PKG I . Mutation of two negatively-charged residues in the PKG I leucine zipper (D26K/E31R) to positivelycharged residues, found in corresponding positions in PKG I , completely abrogated binding to TFII-I and IRAG, without disrupting PKG dimerization.
INTRODUCTION
Signaling complexes including modulatory proteins, protein kinases and phosphatases, and their substrates are held together by specific protein-protein interactions and provide selectivity in signal transduction, because they target the kinases/phosphatases to specific substrates (1) . One of the most thoroughly studied models of protein kinase targeting is that of the cAMPdependent protein kinase (PKA) 1 , a tetrameric enzyme composed of two catalytic subunits bound to a regulatory subunit dimer (2) . Specific "Akinase anchoring proteins" (AKAPs) tether the regulatory subunits to various subcellular locations and place the kinase in close proximity to appropriate substrates (1, 2) . AKAPs have been shown to play an important role in determining the specificity of PKA signaling. They share a common binding motif of an amphipathic helix that interacts with a hydrophobic pocket within the extreme N-terminus of the PKA regulatory subunit dimer (3) . A peptide modeled after the binding motif of AKAP Ht31 disrupts PKA anchoring in intact cells, and experiments with this peptide have shown that PKA phosphorylation of specific substrates and regulation of many cellular processes, such as cardiomyocyte contractiliy, depends on proper localization of the kinase (2, 4) .
The cGMP-dependent protein kinases (PKGs) are highly homologous to PKAs, but PKGs exist as homodimers, with the regulatory and catalytic domains located on a single peptide chain (5) . Two types of PKGs have been identified in mammalian cells: type I PKG (PKG I) exists as two different splice variants from the same gene (PKG I and PKG I ), with distinct N-terminal dimerization domains but identical regulatory and catalytic domains; type II PKG (PKG II) is encoded by a separate gene and shares with PKG I about 80% homology in the regulatory and 75% homology in the catalytic domain (5) . The sequences of PKGs and the PKA regulatory subunits diverge most at their extreme N-termini, the region which is responsible for PKA dimerization and anchoring, and which is unique between the PKG I splice variants. The N-termini of PKA regulatory subunits form a four-helix bundle, while heptad leucine/isoleucine repeats in the Ntermini of PKGs suggest a leucine zipper domain (3, 5) . The latter prediction is supported by sitedirected mutagenesis of PKG I , and solution NMR analysis of amino acids 1-39 of PKG I (6, 7) .
Several proteins which interact specifically with either PKG I or PKG I bind to the unique N-terminal leucine zipper domains (8) (9) (10) (11) . Two proteins known to bind PKG I , but not I , are the general transcriptional regulator TFII-I and the inositol 1,4,5-trisphosphate receptor-associated PKG substrate (IRAG) (10, 11) . We characterized the interaction between TFII-I and PKG I in vitro and in vivo, and found that TFII-I phosphorylation by PKG I in vivo enhanced transcriptional activation of a serum response factor-dependent reporter gene (10) . TFII-I appears to be a molecular scaffold, binding to a wide variety of DNA elements (serum response element, Inr, E-box), and coordinating the activity of multiple transcription factors (serum response factor, USF-1, Myc, Phox1), histone deacetylases, and signaling molecules (PKG I , Bruton's tyrosine kinase, Src kinase) (12, 13) . TFII-I co-localizes with PKG I in intact cells and may serve to position the kinase to phosphorylate other proteins in a multiprotein complex (10) . IRAG also exists in a multiprotein complex which includes PKG I , the inositol 1,4,5-trisphosphate receptor, phospholamban, and other proteins (11, 14) . PKG I phosphorylation of IRAG inhibits inositol 1,4,5-trisphosphate receptor-dependent Ca 2+ release, leading to smooth muscle relaxation (11, 15) . In the present study, we identified a PKG I -specific interaction motif in TFII-I and IRAG, which consists of a predicted -helical structure with several basic amino acids on one face of the helix; this electropositive region binds to a highly negatively-charged region within the N-terminal PKG I leucine zipper.
EXPERIMENTAL PROCEDURES Cell Culture and Transfections
COS7 cells were grown in Dulbecco's Modified Eagle Media containing 10% fetal bovine serum at 37 o C with 5% CO 2 (10) . COS7 cells were transfected using Polyfect (Qiagen) according to the manufacturer's instructions.
IRAG cloning
IRAG a and IRAG b are N-terminal splice variants from the same gene that share the PKG I binding region (11) . IRAG b (referred to as IRAG throughout the text) was cloned via reverse transcription-PCR using total RNA isolated from primary bovine aortic smooth muscle cells. The coding sequence was cloned in three parts using the following primer pairs: IR1 5'-CATATGCC-CCACATTCCCGAG-3' and IR2 5'-AGCCCCA-CTAAGTTCTGATTTC-3'; IR3 5-'GGATCCGC-AGTGGTGGGAAGATGGC-3' and IR4 5'-GCT GGTAAGGAAGGAATGGG-3'; IR5 5'-GGATC-CATGTGGAGAACCTAAAGAG GACG-3' and IR6 5'-TCCCCTGATGGCAGCAGTGG-3'. All PCR products were ligated into pPCR (16) and sequenced. The sequence was identical to the published bovine IRAG b sequence (11) with the exception of three amino acid changes outside the PKG I -binding region: A222P, which is a proline in rat, human, and mouse IRAG; Q237H, which is a glutamine in other species, but two independent PCR clones contained a histidine; and V768A, which is an alanine in canine IRAG. Full-length IRAG was constructed using internal restriction sites.
DNA Constructs
The plasmid pMyc D was constructed by inserting the following Myc epitope-tag linker into the HindIII/BamHI sites of pcDNA3 (Invitrogen) : 5'-AGCTGCCACCATGGAACAAAAACTCAT-CTCAGAAGAGGATCTGGATG-3' (sense); 5'-GATCCATCCAGATCCTCTTCTGAGATGAG-TTTTTGTTCCAGTGTGGC-3' (antisense). Fulllength IRAG was inserted into pMyc D as a BamHI/NotI fragment in frame and downstream of the Myc-epitope. Myc/His-tagged IRAG (1-415) was constructed by first inserting the PCR product formed by the IR1/IR2 primer pair into BamHI/XhoI digested pMyc D and then excising the Myc-IRAG fragment with NcoI/XbaI and inserting it into NcoI/HindIII-digested pRSET (Novagen) using XbaI/HindIII linkers. A TFII-I (R4) glutathione-S-transferase (GST) fusion protein was constructed in pGEX kgl using the following PCR primers: 5'-AGGATCCTGGG-CAATCGAATTAAATTTG-3' (sense) and 5'-GCGGCCGCTAGGACTGCAAAGCTTTAGTG-3' (antisense). The PCR product was ligated into pPCR and subcloned into pGEX kgl using BamHI and NotI restriction enzymes. GST-tagged PKG I (1-110) (containing the first 110 amino acids unique to PKG I ), pCMVGST D -PKG I (con-taining full-length PKG I ), pCMVGST D -PKG I (containing full-length PKG I ), pRSET B -TFII-Imyc, and pCB6-TFII-I-myc have been described previously (10) .
Site-directed Mutagenesis
For site-directed mutagenesis, PKG I (1-110), TFII-I (R4), or IRAG (1-415) were cloned into the BamHI/SalI sites of the vector pALTER-1 (Promega). Mutagenesis reactions were carried out according to the manufacture's instructions. Mutants were sequenced and inserted into pGEX kgl .
In Vivo Interaction Studies
COS7 cells were harvested 24-48 h post transfection and lysed in buffer A [137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , pH 7.4, 0.1% NP-40, 2 mM phenylmethylsulfonylfluoride, and 10 g/ml of leupeptin and aprotinin]. Lysates were centrifuged at 13,000 x g for 10 min and incubated with glutathione sepharose beads for 1 h. Beads were washed three times in buffer A, boiled in SDS sample buffer, and bound proteins were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotting, using the indicated antibodies and horseradish peroxidase-conjugated secondary antibodies with chemiluminesence detection (17) .
In Vitro Interaction Studies
Full-length human PKG I was purified from baculovirus-infected insect cells as previously described (10) . His/Myc-tagged-full-length TFII-I and His/Myc-tagged IRAG (1-415) were expressed in BL21 E. coli and purified using nickel column chromatography according to the manufacturer's protocol (Novagen). GST and GST fused to the N-terminal 110 amino acids of PKG I were produced in DH5 E. coli. Overnight cultures were diluted 1:10 and allowed to grow for 1 h shaking at 37 o C. Isopropyl--Dthiogalactopyranoside was added to a final concentration of 1 mM, and cultures were grown for an additional 5 h. The bacteria were harvested by centrifugation, resuspended in ice-cold buffer A, and disrupted by sonication. Lysates were centrifuged at 13,000 x g for 10 min and incubated with glutathione sepharose beads for 1 h. Beads were washed three times in buffer A, and aliquots of the beads were analyzed by SDS-PAGE and Coomassie blue staining and compared to a bovine serum albumin standard to determine the amount of bound GST-fusion protein.
In pulldown experiments, equal amounts of GST-fusion proteins (20 g) immobilized on glutathione sepharose beads were incubated with 200 l of buffer A containing 1 g/ml of the test protein. After a 1 h incubation, the beads were washed three times in buffer A, boiled in SDS sample buffer, and bound proteins were analyzed by SDS-PAGE and immunoblotting as described above.
To test the effect of increasing salt concentrations on the TFII-I/PKG I interaction, GST-TFII-I (R4) was immobilized on glutathione beads and incubated for 1 h with 200 ng purified PKG I in 50 mM Tris HCl pH 7.0, 0.1% NP40, containing the indicated amount of NaCl (50-400 mM). After three washes in the same binding buffer, binding was analyzed by SDS-PAGE/immunoblotting.
Data Presentation
Western blots and autoradiographs are shown from representative experiments that were reproduced at least three times with similar results.
RESULTS

TFII-I and IRAG interact specifically with fulllength PKG I but not PKG I in vivo.
We previously found that TFII-I bound to the N-terminus of PKG I , but not to the same region of PKG I (10) . To compare the binding of TFII-I to full-length PKG I versus PKG I in intact cells, COS7 cells were transfected with the vector pCB6-TFII-I-myc plus either pCMVGST D -PKG I , pCMVGST D -PKG I , or pCMVGST D (parent vector). Cell lysates were incubated with glutathione sepharose beads, and washed beads were analyzed by SDS-PAGE and immunoblotting with an antibody specific for the Myc-epitope on TFII-I.
TFII-I was pulled down by GST-tagged PKG I but not by GST-tagged PKG I or by GST alone (Fig. 1A) . We performed similar experiments using full length Myc-tagged IRAG in place of TFII-I, and as reported by Schlossmann et al. (11) , found that IRAG interacts specifically with PKG I (Fig. 1B) . Thus, even though TFII-I and IRAG are both PKG substrates, and PKG I and PKG I have identical catalytic subunits, PKG I did not interact with TFII-I or IRAG under the experimental conditions used in the GST pulldown assay. Co-immunoprecipitation of endogenous TFII-I or IRAG with PKG I has been shown previously (10, 11) .
Electrostatic interactions appear important for the PKG I /TFII-I interaction.
Ammendola et al. (15) mapped the interaction between PKG I and IRAG to a highly charged region near the N-terminus of IRAG and suggested that the association between IRAG and PKG I was likely mediated by ionic interactions. TFII-I has no significant sequence similarity to IRAG, but it contains six 90 amino acid-long Irepeats (R1-R6), each containing a putative helixloop-helix motif, and we previously showed that PKG I interacts with amino acids 491-628 of TFII-I, corresponding to R4 (10) . To determine whether the PKG I /TFII-I interaction might involve electrostatic forces between charged amino acid residues, we performed in vitro binding assays with purified proteins in the presence of increasing salt concentrations; we found that the interaction was disrupted by 400 mM NaCl ( Fig. 2A) . At this concentration, NaCl had no effect on either GST binding to the glutathione sepharose beads or on the stability of the PKG I leucine zipper (Fig.2B) . The latter was determined by examining the stability of hetero-dimers formed between full-length PKG I and GST-tagged PKG I (1-110) in co-transfected COS7 cells. GST-PKG I (1-110) was isolated on glutathione beads in the presence of increasing salt concentrations, and full-length PKG I associated with the immobilized leucine zipper domain was detected using an antibody specific for the Cterminus of PKG I. These results suggest that high salt concentrations may interfere with important ionic interactions between PKG I and TFII-I, although we cannot exclude the possibility that increasing salt concentrations could also destabilize the structure of TFII-I (R4). Acidic residues within the PKG I leucine zipper mediate its interaction with TFII-I and IRAG.
Since TFII-I and IRAG bound specifically to PKG I and not PKG I , and since both proteins may bind via salt-sensitive ionic interactions, we reasoned that charged residues within the PKG I leucine zipper would be important for binding, and that these residues should differ between both PKG isoforms.
We aligned the N-terminal primary sequences of PKG I and I and looked for residues with opposite charges, i.e. a basic amino acid in one protein and an acidic amino acid in the other (Fig. 3A) . We then mutated each of these residues in PKG I , changing the charge to that in PKG I , and tested the mutants for interaction with TFII-I and IRAG. We also mutated charged residues in PKG I that were Nterminal to the alignment with PKG I . A D26K or E31K mutation completely disrupted the interaction with TFII-I, while an E16K mutation reduced the interaction, and other mutations were without significant effect (Fig. 3B) .
To test the interaction of the mutants with IRAG, we used a construct consisting of the first 415 amino acids of IRAG fused to both Myc-and His-tags, because full-length IRAG is proteolytically degraded when expressed in E. coli. 2 The truncated IRAG protein was still partially degraded yielding several bands on Western blots (Fig. 3C) . The same two N-terminal PKG I mutations that ablated interaction with TFII-I noticeably reduced the interaction with IRAG, while the other mutations were without effect (Fig.  3C) .
Since the interaction of PKG I with IRAG was not completely eliminated by any of the mutations, we tested another set of mutants, using our charge reversal strategy, with the exception of leucine 30 in PKG I which we changed to a lysine found in PKG I (Fig. 4A) . The interaction of PKG I with TFII-I was completely disrupted by the mutations D22K, E27K, E29K, and D26K/E31R, and was reduced by an E17K mutation (Fig. 4B) . Interaction with IRAG was only disrupted by the E29K and D26K/E31R mutations (Fig. 4C) . While the E29K mutant disrupted the interaction with both TFII-I and IRAG, E27K only affected the interaction with TFII-I. Thus, while not strictly identical, acidic residues within the same region of the PKG I leucine zipper (E17-E31) are involved in the interaction with both TFII-I and IRAG. The E29K and D26K/E31R mutations do not disrupt dimerization of PKG I .
The interaction between PKG I and troponin T or the myosin-binding subunit of myosin phosphatase is disrupted by alanine mutations of two key leucine/isoleucine residues in the Nterminal leucine zipper domain, which presumably interfere with dimer formation of PKG I (7, 8, 18) . Therefore, it was important to determine whether the two PKG I mutants that completely disrupted interaction with TFII-I and IRAG could form stable dimers. COS7 cells were transfected with constructs expressing GST, GST-PKG I (1-110) E29K or mutant D26K/E31R, and co-transfected with full-length PKG I containing the corresponding mutations. GST or GST-tagged proteins were isolated on glutathione beads, and dimerization was detected by association of the full-length mutant protein with the mutant PKG I (1-110). As shown in Fig. 5 , dimer formation was not disrupted in either mutant protein. We also examined dimerization using gel filtration chromatography which was performed similarly to Richie-Jannetta et al. (7) . The two full-length mutant PKG I proteins were expressed in COS7 cells and were analyzed simultaneously with wild type PKG I and an N-terminally truncated form of PKG I which did not form dimers in experiments performed as described in Fig. 5 . Mutant PKG I E29K and D26K/E31R eluted from the gel filtration column at the same position as wild type kinase, which was several fractions before the momomeric PKG I (data not shown). In addition, we performed circular dichroism spectroscopy to examine the helical content of PKG I
(1-110) wild type and mutant D26K/E31R; we found that the wild type and mutant proteins produced very similar spectra with minima at 208 and 222 nm characteristic forhelical proteins (data not shown). These results suggest that the D26K/E31R mutations do not grossly alter the structure of the leucine zipper and do not interfere with dimer formation. Small clusters of basic residues within TFII-I and IRAG mediate binding to PKG I .
Since acidic residues within the N-terminal leucine zipper of PKG I were necessary for the interaction with TFII-I, we reasoned that basic residues within the sequence of TFII-I may mediate binding to PKG I . The TFII-I (R4) domain contains a small cluster of basic amino acids, residues 526-532 (Fig. 6A) . The six Irepeat domains of TFII-I have conserved sequences and are thought to fold into helix-loophelix structures, but only R4 was required for binding to PKG I (10, 19) . By aligning residues 523-534 of R4 with the corresponding residues of the other repeats, we observed that three of four basic amino acids in the cluster are not conserved among the other repeats; in fact, one or more of the other repeats contain an acidic residue in these positions, suggesting that opposite charges do not interfere with folding of the domain (Fig 6A) . For example, K529 in TFII-I (R4) corresponds to aspartate in the second and fifth repeat, and we can infer that changing this lysine to aspartate will not disrupt the secondary or tertiary structure of R4. In addition, alanine scanning was used to further characterize critical residues. Mutation of R531 (a conserved basic amino acid in all repeats) was not examined, because change of this residue to alanine caused a dramatic loss in protein solubility, indicating that this mutation disrupted stable protein folding. Binding of purified fulllength PKG I to various GST-tagged TFII-I R4 mutants was examined in an in vitro pulldown assay. While all mutants shown in Fig. 6B disrupted the interaction with PKG I to some degree, the R526E and R526A/K529A mutations had the greatest effect. In contrast, site-directed mutagenesis of neighboring, non-charged amino acids (V525A and Q544E) had no effect on the PKG I /TFII-I (R4) interaction (data not shown).
The interaction of IRAG with PKG I has been mapped to a 32 amino acid peptide corresponding to residues 100 to 132 of IRAG [ Fig.7A and (15) ]. To determine residues involved in the binding of IRAG to PKG I , pairs of basic amino acids were mutated to alanines, and the various GST-tagged IRAG mutants were tested for their ability to interact with PKG I in an in vitro pulldown assay. Mutation of residues R120, R124, and R125 to alanine had a major effect on the binding, while mutation of R127, K128, and R130 reduced the interaction between IRAG and PKG I (Fig.  7B) . The multiple bands observed in the anti-GST blot are the result of proteolysis of IRAG (1-415), as described above. Secondary structure predictions suggesthelical structures for the regions within TFII-I and IRAG that bind to PKG I .
As mentioned earlier, Roy et al. (19) had predicted that the beginning of each I-repeat in TFII-I, including the region of R4 which interacted with PKG I (Fig. 6) (20, 21) . The PKG I -interacting region of TFII-I (Fig. 6A ) is predicted to be -helical between amino acids 526-545 by PSIPRED and between amino acids 523-545 by NPS@. The PKG Iinteracting region of IRAG (Fig. 7A ) is predicted to be -helical between amino acids 101-124 by PSIPRED and between amino acids 103-124 by NPS@. In addition, Chou-Fassman analysis using the MacVector program (Accelrys) (22) predicts that the PKG I -interacting regions of TFII-I and IRAG form -helical structures. Interestingly, when these regions were plotted on helical wheels, the basic residues of TFII-I and IRAG proposed to contact PKG I were located on one side of the predicted helices. While these results are highly suggestive, it should be noted that further structural studies are needed to confirm the helical nature of the PKG I interaction motif.
Mutation of critical residues within full-length TFII-I and IRAG disrupt their interaction with PKG I
We asked whether specific mutations in fulllength TFII-I or IRAG would be sufficient to disrupt their interaction with PKG I in intact cells. We co-transfected COS7 cells with vectors expressing GST-tagged full-length PKG I and Myc-tagged wild type or mutant TFII-I or IRAG, and found that full-length TFII-I containing the R526A/K529A mutations and full-length IRAG containing the R124A/R125A mutations no longer interacted with PKG I in vivo (Fig. 8A and B) .
DISCUSSION
We used site-directed mutagenesis and in vitro plus in vivo protein binding assays to identify molecular determinants of the isotype-specific PKG I interaction with TFII-I and IRAG. Both TFII-I and IRAG bind a region of the PKG I leucine zipper that is rich in acidic amino acids, while the PKG I binding regions within TFII-I and IRAG contain basic amino acids residues and likely form -helices. The primary sequences of the PKG I interaction sites in TFII-I and IRAG otherwise show no similarities, but orientation of the basic amino acids on one face of a presumed -helix may be important. Based on effects of specific mutations in both PKG I and its interaction partners, combined with secondary structure predictions, we propose a model for PKG Ispecific anchoring, consisting of several positively-charged amino acids arranged on one side of an -helix which interact with a cluster of negatively-charged residues in the PKG I leucine zipper. Specific mutations in the PKG I leucine zipper (D26K/E31R) disrupted interaction with both TFII-I and IRAG. Since the D26K/E31R mutations change negatively-charged residues in PKG I to positively-charged residues found in analogous positions in PKG I , these results may provide an explanation for PKG I isotype-specific binding.
The binding affinity of PKG I for its interaction partners is not known, but under our experimental conditions, detection of protein/ protein interactions in pull-down assays using GST-tagged proteins requires a K D of approximately 1 M or less (e.g. the interaction between GST-tagged Raf-1 kinase and Rap1A is lost during multiple washes) (23) . The effect of a single amino acid change on the binding affinity of two protein partners is difficult to predict, but a single charge change in the interface between two proteins that associate via electrostatic interactions can result in a >100-fold decrease in binding affinity (23) . Since the single amino acid change E29K in PKG I was able to disrupt the interaction of PKG I with both TFII-I and IRAG, this residue appears to be crucial for binding and the charge change may result in repulsive instead of attractive forces between PKG I and its partners.
Although the anchoring of PKG I to TFII-I and IRAG shared several common features, there were some noticeable differences. For example, the PKG I E27K mutant completely prevented interaction with TFII-I, while the interaction with IRAG was not detectably affected. Thus, specific mutations in the PKG I leucine zipper may disrupt interaction with a subset of PKG I interacting proteins. It may be possible to exploit this selective association of PKG I with intracellular targets to dissect specific functions of the kinase.
Our work concentrated on the two known PKG I -specific interacting proteins, but preliminary data suggest that there are additional PKG I -specific interacting proteins whose binding to the N-terminal region of PKG I is prevented by the D26K/E31R mutation. We incubated cell lysates from 35 S methionine/cysteine-labeled cells with immobilized GST-PKG I (1-110) wild type or mutant D26K/E31R, or GST alone; we eluted the bound proteins with glutathione and analyzed them by SDS-PAGE and autoradiography. Several proteins between 25 and 80 kDa interacted specifically with wild type but not mutant PKG I (1-110) D26K/E31R, or GST, suggesting that these proteins may share a common binding motif with TFII-I and IRAG. 2 Work is in progress to identify these proteins.
The leucine zipper domain of PKG I binds to a C-terminal leucine zipper domain in the MBS of myosin phosphatase, and mutations in the MBS leucine zipper that eliminate MBS homodimerization also disrupt interaction with PKG I ; however, specific residues that mediate the interaction are not known (8, 24) . Like MBS, the PKG interacting protein GKAP42 interacts specifically with PKG I , but not with PKG I (9). Several other PKG I interacting proteins have been identified, but binding of PKG I was either not tested (25, 26) , or the proteins bound to both PKG I isoforms without apparent specificity (18, 27) . Heterodimers between PKG I and I have not been reported (5), and we were unable to detect heterodimerization in experiments that were performed analogous to those described in Fig. 5 . 2 Binding of AKAPs to the N-terminal dimerization domain of the regulatory subunits of PKA has been extensively studied (3) . In contrast to the proposed PKG I and I leucine zipper domains mediating parallel homo-dimerization (5), PKA regulatory subunits form an anti-parallel dimer through a X-type four-helix bundle motif (28) . Since the extreme N-termini of PKAs and PKGs are so different, one cannot extrapolate from the structure of the PKA/AKAP interaction to the structure of the PKG I interaction motif.
Presently, there are no published crystal structures for PKG I, or any of its domains.
However, similar to the Ht31 peptide that disrupts PKA anchoring (2), inhibitory peptides that disrupt PKG I or I anchoring can be devised to study the importance of kinase targeting for cGMP signaling.
TFII-I and IRAG may function as scaffolding proteins in the center of multi-protein complexes and target PKG I to phosphorylate not only TFII-I and IRAG, but also other proteins in the complex (10, 14, 15) . However, while the physiological functions of TFII-I and IRAG have been studied in some detail, relatively little is known about the significance of the interaction between PKG I and TFII-I or IRAG (10) (11) (12) 14) . We previously showed that TFII-I transcriptional activity is modulated by PKG I but not I (10), and preliminary data suggest that the interaction between PKG I and IRAG at the endoplasmic reticulum may be sufficient to prevent nuclear translocation of PKG I and transcriptional regulation by the kinase. 3 In conclusion, our results begin to define the molecular mechanisms involved in PKG I interaction with target proteins. Undoubtedly, the completion of structural studies that solve the solution or crystal structure of a PKG I Nterminal fragment complexed with either an IRAG or TFII-I peptide will define the precise topology of the binding interface. (19) . Numbers to the left refer to the position of the first amino acid shown for each repeat within the full-length protein. Residues in R4 that were mutated for the experiments in panel B are underlined, some of the other repeats have acidic amino acids in these positions. B: GST and GST-TFII-I (R4) wild type (WT) and the indicated mutants were produced in E. coli, and immobilized on glutathione beads. Beads loaded with 20 g of recombinant protein were incubated for 1 h with 200 ng of purified full-length PKG I , washed, and analyzed by SDS-PAGE and immunoblotting using antibodies specific for the C-terminus of PKG I (upper panel) or for GST (lower panel). The lower panel shows that similar amounts of GST, GST-TFII-I (R4) wild type or mutant proteins were used in the pulldowns. 
